HOW WE HELP
NET CANCER AWARENESS
Easily missed.
Take a closer look at neuroendocrine cancer.
Understanding RLT in NETs
ENGLISH
FRENCH
NEUROENDOCRINE TUMOURS (NETs) OVERVIEW
-
Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
-
NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
-
NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
-
NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
-
The cause of NETs is currently unknown.
CNETS NEWS
SHARED CARE PATIENT SURVEY
SHARED CARE PATIENT SURVEY CNETS wants to hear YOUR STORY to help make NET care better. You can share with us by completing the survey linked to this post. The information collected from this [...]
NET Biomarkers Guideline Published in JAMA Oncology
CNETS is thrilled to announce the publication of a biomarker guideline and patient supplements in JAMA Oncology. Citation: Loree JM, Chan D, Lim J, et al. Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic [...]
Welireg (belzutifan): pCPA Negotiations
The pan-Canadian Pharmaceutical Alliance (pCPA) negotiation process for Welireg (belzutifan) concluded on 2024-08-30. Indication(s): Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) [...]
Expansion of public funding for Lutathera in Ontario to now include pNETs patients
Luththera: Funding update for radionuclide therapy for pancreatic neoroendocrine tumours (pNETs). Effective November 7, 2023, Ontario Health will fund the use of Lutathera to treat eligible pancreatic neuroendocrine tumour (pNETs) patients. This is in addition [...]
Update on Lutathera pCPA Negotiations for pNETs
One step closer to access to Lutathera for pNETs patients! The pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with Advanced Accelerator Applications for Lutathera (lutetium 177 dotatate) in pNETs concluded on 2023-10-17. Negotiation Status: Concluded with [...]
Board Recruitment Announcement
Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the service of a great cause? Well, [...]
CNETS PRIORITIES
AWARENESS
– Raise awareness of NET cancer to the general public & the medical community
– Participate in World NET Cancer Day Activities
SUPPORT
– In-person peer-led support groups meetings
– Dedicated patient email and phone support
– Online private support groups for patients & caregivers
EDUCATION
